Sidhu v. Bayer Healthcare Pharmaceuticals Inc.

Background

Priya Sidhu alleged that Bayer Healthcare Pharmaceuticals Inc. markets and sells Mirena, a hormonal intrauterine device, without disclosing that it significantly increases users’ risk of breast cancer. Sidhu alleged that she used Mirena in California from February 2019 through February 2022, paid $50 out of pocket, reviewed the patient brochure, and would not have purchased it—or would have paid significantly less—if Bayer had disclosed the alleged risk. She asserted claims for breach of the implied warranty of merchantability, unjust enrichment, fraud, negligence, and violations of California’s Unfair Competition Law, Consumer Legal Remedies Act, and False Advertising Law. She also sought to represent California and nationwide classes.

Bayer moved to dismiss under Federal Rules of Civil Procedure 12(b)(1), which concerns federal subject-matter jurisdiction, and 12(b)(6), which tests whether a complaint states a legally sufficient claim. Bayer also moved to strike the punitive-damages request and class allegations.

Rulings on standing and judicial notice

The court denied Bayer’s request to take judicial notice of 12 exhibits without prejudice. The court explained that Bayer had not identified the specific facts in the studies, Food and Drug Administration materials, and websites that it wanted the court to notice.

The court denied Bayer’s motion to dismiss for lack of injury. Although Sidhu did not have breast cancer, the court held that it could not evaluate the competing scientific evidence at the pleading stage. The court advised Sidhu to provide more concrete allegations in an amended complaint supporting the alleged undisclosed or minimized risk.

The court granted Bayer’s motion to dismiss all claims for injunctive relief without leave to amend because Sidhu did not allege that she intended or was willing to purchase Mirena in the future.

Common-law claims and nationwide class issues

The court granted Bayer’s motion to dismiss the common-law claims for failure to identify which state law applied, with leave to amend. The court also directed Sidhu to address whether she could assert California law for class members outside California and noted that courts in the Ninth Circuit have generally held that a plaintiff lacks standing to assert claims under the laws of states where the plaintiff did not reside or suffer injury.

Learned intermediary doctrine

The court held that the learned intermediary doctrine applies to claims involving prescription drugs or medical devices supplied through a physician-patient relationship. Under that doctrine, the manufacturer’s duty to warn generally runs to the prescribing physician rather than directly to the patient. The court found that Sidhu had not adequately alleged what Bayer told or failed to tell her physician, or how an adequate warning to the physician would have affected the prescription. Bayer’s motion to dismiss all counts under the learned intermediary doctrine was granted with leave to amend.

The court also found that Sidhu had not clearly pleaded a design-defect theory. It required her to state that theory more clearly and provide supporting facts, but did not decide whether the learned intermediary doctrine would ultimately apply to such a theory.

Federal preemption

Bayer argued that federal law preempted Sidhu’s failure-to-warn claims. The court applied the framework for determining whether federal law made it impossible for Bayer to comply with both federal labeling requirements and state law. The court held that Sidhu had not alleged what information Bayer provided to the Food and Drug Administration or when it provided that information. Without those allegations, the court could not determine whether the studies Sidhu cited were newly acquired information that Bayer could have used to change Mirena’s labeling under federal regulations. Bayer’s motion to dismiss all failure-to-warn claims as preempted was granted with leave to amend.

The court declined to decide whether a design-defect claim would be preempted because Sidhu had not adequately alleged such a claim.

Fraud-based claims

Sidhu clarified that her fraud theory was based on an omission rather than an affirmative misrepresentation. The court held that she adequately alleged Bayer’s knowledge and intent at this stage because she identified studies that allegedly showed the increased risk and alleged that Bayer failed to disclose the information. However, because the learned intermediary doctrine applied, Sidhu also needed to plead reliance by her physician. She had not done so.

The court granted Bayer’s motion to dismiss, with leave to amend, Sidhu’s common-law fraud claim and her claims under the fraudulent prong of the Unfair Competition Law, the Consumer Legal Remedies Act, and the False Advertising Law.

Other Unfair Competition Law claims

The court granted Bayer’s motion to dismiss, with leave to amend, Sidhu’s UCL claim under the unlawful prong. That claim depended on other claims that the court had dismissed, and the court held that the UCL claim therefore also failed as pleaded. The court did not consider Sidhu’s argument concerning the Sherman Act because she raised it for the first time in her opposition rather than in the complaint.

The court also granted Bayer’s motion to dismiss, with leave to amend, Sidhu’s UCL claim under the unfair prong. The court held that the complaint based that claim on the same conduct underlying the fraud and unlawful UCL claims, which could not survive as pleaded.

Unjust enrichment and implied warranty

The court denied Bayer’s motion to dismiss the unjust-enrichment claim on the ground that Sidhu had failed to state her consumer-protection claims. The court rejected that argument and applied California law to the unjust-enrichment claim. Separately, however, the court granted with leave to amend Bayer’s motion to dismiss the unjust-enrichment claim, along with the UCL and False Advertising Law claims, for lack of equitable jurisdiction because Sidhu had not adequately alleged that she lacked an adequate legal remedy.

The court denied Bayer’s motion to dismiss the implied-warranty claim for failure to state a claim. Although the complaint was unclear, Sidhu alleged that Mirena was not fit for its intended purpose and created a significantly elevated risk of breast cancer. The court held that such a risk, if proven, would constitute a safety hazard.

Negligence and punitive damages

The court granted Bayer’s motion to dismiss the negligence claim with leave to amend. Applying California law, the court held that Sidhu had not alleged facts supporting an exception to the economic-loss rule, which generally limits tort recovery for purely economic losses from a defective product unless the plaintiff alleges additional property damage or personal injury.

The court granted Bayer’s motion to dismiss the request for punitive damages with leave to amend because the request depended on fraud claims that the court had dismissed. The court separately denied Bayer’s motion to strike the punitive-damages request, finding that Bayer had not met the standard for striking material from a pleading and that Sidhu might be able to plead punitive damages properly in an amended complaint.

Class allegations and final order

The court denied Bayer’s motion to strike the class allegations. Because Sidhu was receiving leave to amend all of her claims, the court could not conclude that a class action could not be maintained under any circumstances alleged in an amended complaint.

Judge Beth Labson Freeman ordered Sidhu to file an amended complaint within 60 days. The order stated that failing to meet the deadline or failing to correct the identified deficiencies would result in dismissal of the deficient claims with prejudice, and that any amendments could not exceed the scope permitted by the order.